AgingResearch.NewsJoin free

Alnylam Pharmaceuticals

CompanyUnited StatesFounded 2002

Wikidata

Alnylam Pharmaceuticals develops 7 assets, the furthest in phase 3 (Nucresiran in hATTR-PN). Mostly oligonucleotide acting on proteostasis, TTR and AGT; based in the United States, founded in 2002.

7
Assets
Furthest stage
Phase 3
9
Trials
8
Signals

Pipeline

7

  • Nucresiran

    Silences hepatic TTR messenger RNA, reducing transthyretin production and amyloid formation.

    Phase 3, Oligonucleotide, Proteostasis, TTR, hATTR-PN, hereditary transthyretin-mediated amyloidosis with polyneuropathy

  • Vutrisiran

    Silences hepatic TTR messenger RNA, reducing transthyretin production and subsequent amyloid deposition.

    Phase 3, Oligonucleotide, Proteostasis, TTR, transthyretin amyloidosis (attr) with cardiomyopathy

  • Zilebesiran

    Silences hepatic angiotensinogen production through RNA interference, reducing renin-angiotensin signaling and blood pressure.

    Phase 3, Oligonucleotide, AGT, high cardiovascular risk, high risk cardiovascular disease

4 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms6
  • Trials9
  • Signals17
  • Similar companies6

Papers

Intelligence